0001551152 false Common Stock, $0.01 Par Value ABBV 0001551152 2021-05-07 2021-05-07 0001551152 us-gaap:CommonStockMember exch:XNYS 2021-05-07 2021-05-07 0001551152 exch:XCHI us-gaap:CommonStockMember 2021-05-07 2021-05-07 0001551152 abbv:SeniorNotes1.500Percentdue2023Member exch:XNYS 2021-05-07 2021-05-07 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2021-05-07 2021-05-07 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2021-05-07 2021-05-07 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2021-05-07 2021-05-07 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2021-05-07 2021-05-07 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2021-05-07 2021-05-07 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2021-05-07 2021-05-07 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2021-05-07 2021-05-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 7, 2021

 

ABBVIE INC.

(Exact Name of Registrant as specified in its charter)

 

Delaware   001-35565   32-0375147
(State or other Jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

_______________________________________________

 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange
Chicago Stock Exchange
1.500% Senior Notes due 2023   ABBV23B   New York Stock Exchange
1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange
1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange
0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange
2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange
2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange
2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange
1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 7, 2021. The following is a summary of the matters voted on at that meeting.

 

  (1) The stockholders elected AbbVie’s Class III Directors with terms expiring in 2024, as follows:

 

Name   For   Against   Broker Non-Votes
Roxanne S. Austin   1,176,814,309   40,193,567   266,940,608
Richard A. Gonzalez   1,143,418,886   73,588,990   266,940,608
Rebecca B. Roberts   1,178,818,824   38,189,052   266,940,608
Glenn F. Tilton   1,092,161,771   124,846,105   266,940,608

 

  (2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2021, as follows:

 

For   Against   Abstain    
1,443,141,768   38,474,335   2,332,381    

 

  (3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2021 annual meeting, as follows:

 

For   Against   Abstain   Broker Non-Votes
1,088,078,054   122,760,887   6,168,935   266,940,608

 

  (4) The stockholders approved the Amended and Restated 2013 Incentive Stock Program, as follows:

 

For   Against   Abstain   Broker Non-Votes
1,151,977,015   60,300,643   4,730,218   266,940,608

 

  (5) The stockholders approved the Amended and Restated 2013 Employee Stock Purchase Plan for Non-U.S. Employees, as follows:

 

For   Against   Abstain   Broker Non-Votes
1,179,691,622   33,184,479   4,131,775   266,940,608

 

  (6) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:

 

For   Against   Abstain   Broker Non-Votes
1,200,648,034   12,015,517   4,344,325   266,940,608

 

  (7) The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows:

 

For   Against   Abstain   Broker Non-Votes
435,784,510   770,846,870   10,376,496   266,940,608

 

  (8) The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows:

 

For   Against   Abstain   Broker Non-Votes
330,233,388   831,267,134   55,507,354   266,940,608

  

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      ABBVIE INC.
       
Date: May 10, 2021 By: /s/ Laura J. Schumacher
      Laura J. Schumacher
      Vice Chairman, External Affairs, Chief Legal Officer, and Corporate Secretary

 

Common Stock, $0.01 Par Value ABBV

 

 

 

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more AbbVie Charts.